This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on ISI (2)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Bacterial Infections  • Neurology  • Dementias  • Diagnosis  • Adverse Effects  • Alert me on articles by topic

Arch Intern Med. 2001;161:1909-1910.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In an article titled "Statins and the Risk of Dementia" published in the November 11, 2000, issue of Lancet, Jick and colleagues¹ from Boston, Mass, reported an epidemiologic, observational, nested case-control study of subjects enrolled in the United Kingdom-based General Practice Research Database. Records of patients aged 50 to 89 years were classified into 1 of 3 groups: group 1 comprised individuals who received at least 1 prescription of lipid-lowering agents (LLAs) within the previous 6 months; group 2, all individuals with a clinical diagnosis of untreated hyperlipidemia; and group 3, a randomly selected group of other individuals.

From this base population, all cases with a computer-recorded diagnosis of dementia or Alzheimer disease (AD) entered between 1992 and 1998 were identified, and each case was matched with up to 4 controls. Excluded from the study were patients with diagnoses of alcoholism or drug abuse, cancer, motor neuron disease, parkinsonism, . . . [Full Text of this Article]